BioSpace News Archive

Takeda announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility program.

Spirair ™, an early-stage company pioneering minimally invasive solutions that help ENTs advance care for their patients, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SeptAlign™ System.

Alterome Therapeutics, Inc. today reported promising preclinical data from their lead pipeline candidate, ALTA-2618, a mutation-selective inhibitor for AKT1 E17K driven cancers.

Synchron , the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the launch of a community-centered BCI registry to bring patients, carers and clinicians together to learn how BCI is being designed to provide benefit to people with limited mobility.

Ferring Pharmaceuticals today announced the presentation of three-year follow-up data from the Phase 3 study1 at the 39th Annual European Association of Urology (EAU) Congress.

Vizgen Expands Single-Cell Spatial Transcriptomics Offering with Introduction of MERSCOPE ® Ultra Platform and MERFISH 2.0 Chemistry at AACR 2024.

Model N announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners, a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses.

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California.

Autonomix Medical, Inc. today announced that it will present at the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker event on Thursday, April 11, 2024 at 12:00 PM ET.

Nuvectis Pharma, Inc. (NASDAQ: NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved for the treatment of NSCLC.